title: [Drug treatment of postmenopausal osteoporosis. What's New in 2006].
authors.affiliation: Service de rhumatologie, Hôpital Cochin, Paris (75).
authors.forename: Christian
authors.initials: C
authors.lastname: Roux
authors.forename: Karine
authors.initials: K
authors.lastname: Briot
authors.forename: Nathalie
authors.initials: N
authors.lastname: Dumarcet
authors.forename: Michel
authors.initials: M
authors.lastname: Bourgoin
authors.forename: Roland
authors.initials: R
authors.lastname: Chapurlat
authors.forename: Sophie
authors.initials: S
authors.lastname: Christin-Maitre
authors.forename: Bernard
authors.initials: B
authors.lastname: Cortet
authors.forename: Dominique
authors.initials: D
authors.lastname: Costagliola
authors.forename: Vincent
authors.initials: V
authors.lastname: Diebolt
authors.forename: François
authors.initials: F
authors.lastname: Lacoin
authors.forename: Brigitte
authors.initials: B
authors.lastname: Letombe
authors.forename: Flavien
authors.initials: F
authors.lastname: Oberlin
authors.forename: Philippe
authors.initials: P
authors.lastname: Orcel
authors.forename: Philippe
authors.initials: P
authors.lastname: Ravaud
authors.forename: Patrick
authors.initials: P
authors.lastname: Seret
authors.forename: Thierry
authors.initials: T
authors.lastname: Thomas
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Vogel
authors.forename: Alexandre
authors.initials: A
authors.lastname: Barna
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Nouyrigat
authors.forename: Marie-Laure
authors.initials: ML
authors.lastname: Veyries
authors.forename: Isabelle
authors.initials: I
authors.lastname: Yoldjian
mesh_terms: D015502:Absorptiometry, Photon; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D019386:Alendronate / Q000008:administration & dosage / Q000627:therapeutic use; D015992:Body Mass Index; D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001851:Bone Diseases, Metabolic / Q000175:diagnosis / Q000628:therapy; D005260:Female; D005264:Femoral Fractures / Q000209:etiology / Q000517:prevention & control; D005500:Follow-Up Studies; D050723:Fractures, Bone / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D008875:Middle Aged; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000627:therapeutic use; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000517:prevention & control; D017410:Practice Guidelines as Topic; D020849:Raloxifene Hydrochloride / Q000008:administration & dosage / Q000627:therapeutic use; D012307:Risk Factors; D016103:Spinal Fractures / Q000209:etiology / Q000517:prevention & control; D013607:Tablets; D019379:Teriparatide / Q000008:administration & dosage / Q000627:therapeutic use; D013876:Thiophenes / Q000008:administration & dosage / Q000627:therapeutic use; D013997:Time Factors
chemical_list: D050071:Bone Density Conservation Agents; D009942:Organometallic Compounds; D013607:Tablets; D013876:Thiophenes; C081587:strontium ranelate; D019379:Teriparatide; D020849:Raloxifene Hydrochloride; D019386:Alendronate